A detailed history of Goldman Sachs Group Inc transactions in Rezolute, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 33,104 shares of RZLT stock, worth $205,244. This represents 0.0% of its overall portfolio holdings.

Number of Shares
33,104
Previous 236,209 85.99%
Holding current value
$205,244
Previous $685,000 78.54%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 14, 2025

SELL
$2.47 - $4.46 $501,669 - $905,848
-203,105 Reduced 85.99%
33,104 $147,000
Q1 2025

May 09, 2025

BUY
$2.73 - $5.57 $644,850 - $1.32 Million
236,209 New
236,209 $685,000

Others Institutions Holding RZLT

About Rezolute, Inc.


  • Ticker RZLT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 38,827,600
  • Market Cap $241M
  • Description
  • Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultr...
More about RZLT
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.